Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction
Ocular surface disorders—and dry eye, in particular—is a leading reason for visits to eye care professionals. It has been generally accepted that meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, as well as being associated with aqueous-deficient dry eye. Yet, researchers...
Gespeichert in:
Veröffentlicht in: | Ophthalmology (Rochester, Minn.) Minn.), 2012-10, Vol.119 (10), p.S1-S12 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | S12 |
---|---|
container_issue | 10 |
container_start_page | S1 |
container_title | Ophthalmology (Rochester, Minn.) |
container_volume | 119 |
creator | Foulks, Gary N., MD, FACS Nichols, Kelly K., OD, PhD Bron, Anthony J., FRCOphth, FMedSci Holland, Edward J., MD McDonald, Marguerite B., MD, FACS Nelson, J. Daniel, MD |
description | Ocular surface disorders—and dry eye, in particular—is a leading reason for visits to eye care professionals. It has been generally accepted that meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, as well as being associated with aqueous-deficient dry eye. Yet, researchers and clinicians have lacked a global consensus on the definition of MGD, its epidemiology, pathophysiology, and management. Various systemic diseases and medications have been associated with the progression of both dry eye and MGD, as have several ocular disorders beyond those directly affecting the surface. It is in the best interest of patients for clinicians to be able to better identify and diagnose MGD, differentiating it from other ocular surface disorders, and to recognize the effects of MGD on the ocular surface, and thus initiate appropriate therapy. This CME activity provides expert insight into the Tear Film and Ocular Surface Society's International Workshop on MGD consensus report, offering practical application of its findings to better manage MGD patient care, particularly for those patients facing or undergoing ocular surgery. |
doi_str_mv | 10.1016/j.ophtha.2012.06.064 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1112679347</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0161642012006240</els_id><sourcerecordid>1112679347</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-bd3167b00fcae84da33a824fd8536733bd9c5c1b102ee996406d13aa4fb252aa3</originalsourceid><addsrcrecordid>eNqFkU9P3DAQxS1UBAv0G1RVjj2Qrcf2OptLJcTflUBILT1bjj0BbxN7ayeg_fY4WsqBS6WRfJjfm_G8R8gXoHOgIL-v52HzNDzpOaPA5lTmEntkBgtRl6IC_onMMgalFIwekqOU1pRSKbk4IIeMUy64gBn5ueo3MTw7_1icveiIHlM6LVYW_eBaZ_Tggj8ttLfFnfb6EfvcKEJb3KFrQu-0L667qXuxTe3ozYSfkP1Wdwk_v73H5PfV5cP5TXl7f706P7stjYBqKBvLQVYNpa3RuBRWc66XTLR2ueCy4ryxtVkYaIAyxLqWgkoLXGvRNmzBtObH5Ntubj7g74hpUL1LBrv8HwxjUgDAZFVzUWVU7FATQ0oRW7WJrtdxq4CqyU21Vjs31eSmojKXyLKvbxvGpkf7LvpnXwZ-7ADMdz47jCoZh96gdRHNoGxw_9vwcYDpnM--d39wi2kdxuizhwpUyhr1a0p0ChRYzpIJyl8Bnleceg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1112679347</pqid></control><display><type>article</type><title>Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Foulks, Gary N., MD, FACS ; Nichols, Kelly K., OD, PhD ; Bron, Anthony J., FRCOphth, FMedSci ; Holland, Edward J., MD ; McDonald, Marguerite B., MD, FACS ; Nelson, J. Daniel, MD</creator><creatorcontrib>Foulks, Gary N., MD, FACS ; Nichols, Kelly K., OD, PhD ; Bron, Anthony J., FRCOphth, FMedSci ; Holland, Edward J., MD ; McDonald, Marguerite B., MD, FACS ; Nelson, J. Daniel, MD</creatorcontrib><description>Ocular surface disorders—and dry eye, in particular—is a leading reason for visits to eye care professionals. It has been generally accepted that meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, as well as being associated with aqueous-deficient dry eye. Yet, researchers and clinicians have lacked a global consensus on the definition of MGD, its epidemiology, pathophysiology, and management. Various systemic diseases and medications have been associated with the progression of both dry eye and MGD, as have several ocular disorders beyond those directly affecting the surface. It is in the best interest of patients for clinicians to be able to better identify and diagnose MGD, differentiating it from other ocular surface disorders, and to recognize the effects of MGD on the ocular surface, and thus initiate appropriate therapy. This CME activity provides expert insight into the Tear Film and Ocular Surface Society's International Workshop on MGD consensus report, offering practical application of its findings to better manage MGD patient care, particularly for those patients facing or undergoing ocular surgery.</description><identifier>ISSN: 0161-6420</identifier><identifier>EISSN: 1549-4713</identifier><identifier>DOI: 10.1016/j.ophtha.2012.06.064</identifier><identifier>PMID: 23034341</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Cyclosporine - administration & dosage ; Dry Eye Syndromes - diagnosis ; Dry Eye Syndromes - metabolism ; Eyelid Diseases - classification ; Eyelid Diseases - diagnosis ; Eyelid Diseases - metabolism ; Female ; Humans ; Keratomileusis, Laser In Situ ; Lacrimal Apparatus Diseases - diagnosis ; Lacrimal Apparatus Diseases - metabolism ; Male ; Meibomian Glands - pathology ; Middle Aged ; Ophthalmic Solutions - administration & dosage ; Ophthalmology ; Tears - metabolism ; Visual Acuity</subject><ispartof>Ophthalmology (Rochester, Minn.), 2012-10, Vol.119 (10), p.S1-S12</ispartof><rights>American Academy of Ophthalmology</rights><rights>2012 American Academy of Ophthalmology</rights><rights>Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-bd3167b00fcae84da33a824fd8536733bd9c5c1b102ee996406d13aa4fb252aa3</citedby><cites>FETCH-LOGICAL-c417t-bd3167b00fcae84da33a824fd8536733bd9c5c1b102ee996406d13aa4fb252aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ophtha.2012.06.064$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,777,781,786,787,3537,23911,23912,25121,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23034341$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Foulks, Gary N., MD, FACS</creatorcontrib><creatorcontrib>Nichols, Kelly K., OD, PhD</creatorcontrib><creatorcontrib>Bron, Anthony J., FRCOphth, FMedSci</creatorcontrib><creatorcontrib>Holland, Edward J., MD</creatorcontrib><creatorcontrib>McDonald, Marguerite B., MD, FACS</creatorcontrib><creatorcontrib>Nelson, J. Daniel, MD</creatorcontrib><title>Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction</title><title>Ophthalmology (Rochester, Minn.)</title><addtitle>Ophthalmology</addtitle><description>Ocular surface disorders—and dry eye, in particular—is a leading reason for visits to eye care professionals. It has been generally accepted that meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, as well as being associated with aqueous-deficient dry eye. Yet, researchers and clinicians have lacked a global consensus on the definition of MGD, its epidemiology, pathophysiology, and management. Various systemic diseases and medications have been associated with the progression of both dry eye and MGD, as have several ocular disorders beyond those directly affecting the surface. It is in the best interest of patients for clinicians to be able to better identify and diagnose MGD, differentiating it from other ocular surface disorders, and to recognize the effects of MGD on the ocular surface, and thus initiate appropriate therapy. This CME activity provides expert insight into the Tear Film and Ocular Surface Society's International Workshop on MGD consensus report, offering practical application of its findings to better manage MGD patient care, particularly for those patients facing or undergoing ocular surgery.</description><subject>Adult</subject><subject>Cyclosporine - administration & dosage</subject><subject>Dry Eye Syndromes - diagnosis</subject><subject>Dry Eye Syndromes - metabolism</subject><subject>Eyelid Diseases - classification</subject><subject>Eyelid Diseases - diagnosis</subject><subject>Eyelid Diseases - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Keratomileusis, Laser In Situ</subject><subject>Lacrimal Apparatus Diseases - diagnosis</subject><subject>Lacrimal Apparatus Diseases - metabolism</subject><subject>Male</subject><subject>Meibomian Glands - pathology</subject><subject>Middle Aged</subject><subject>Ophthalmic Solutions - administration & dosage</subject><subject>Ophthalmology</subject><subject>Tears - metabolism</subject><subject>Visual Acuity</subject><issn>0161-6420</issn><issn>1549-4713</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9P3DAQxS1UBAv0G1RVjj2Qrcf2OptLJcTflUBILT1bjj0BbxN7ayeg_fY4WsqBS6WRfJjfm_G8R8gXoHOgIL-v52HzNDzpOaPA5lTmEntkBgtRl6IC_onMMgalFIwekqOU1pRSKbk4IIeMUy64gBn5ueo3MTw7_1icveiIHlM6LVYW_eBaZ_Tggj8ttLfFnfb6EfvcKEJb3KFrQu-0L667qXuxTe3ozYSfkP1Wdwk_v73H5PfV5cP5TXl7f706P7stjYBqKBvLQVYNpa3RuBRWc66XTLR2ueCy4ryxtVkYaIAyxLqWgkoLXGvRNmzBtObH5Ntubj7g74hpUL1LBrv8HwxjUgDAZFVzUWVU7FATQ0oRW7WJrtdxq4CqyU21Vjs31eSmojKXyLKvbxvGpkf7LvpnXwZ-7ADMdz47jCoZh96gdRHNoGxw_9vwcYDpnM--d39wi2kdxuizhwpUyhr1a0p0ChRYzpIJyl8Bnleceg</recordid><startdate>20121001</startdate><enddate>20121001</enddate><creator>Foulks, Gary N., MD, FACS</creator><creator>Nichols, Kelly K., OD, PhD</creator><creator>Bron, Anthony J., FRCOphth, FMedSci</creator><creator>Holland, Edward J., MD</creator><creator>McDonald, Marguerite B., MD, FACS</creator><creator>Nelson, J. Daniel, MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20121001</creationdate><title>Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction</title><author>Foulks, Gary N., MD, FACS ; Nichols, Kelly K., OD, PhD ; Bron, Anthony J., FRCOphth, FMedSci ; Holland, Edward J., MD ; McDonald, Marguerite B., MD, FACS ; Nelson, J. Daniel, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-bd3167b00fcae84da33a824fd8536733bd9c5c1b102ee996406d13aa4fb252aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Cyclosporine - administration & dosage</topic><topic>Dry Eye Syndromes - diagnosis</topic><topic>Dry Eye Syndromes - metabolism</topic><topic>Eyelid Diseases - classification</topic><topic>Eyelid Diseases - diagnosis</topic><topic>Eyelid Diseases - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Keratomileusis, Laser In Situ</topic><topic>Lacrimal Apparatus Diseases - diagnosis</topic><topic>Lacrimal Apparatus Diseases - metabolism</topic><topic>Male</topic><topic>Meibomian Glands - pathology</topic><topic>Middle Aged</topic><topic>Ophthalmic Solutions - administration & dosage</topic><topic>Ophthalmology</topic><topic>Tears - metabolism</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Foulks, Gary N., MD, FACS</creatorcontrib><creatorcontrib>Nichols, Kelly K., OD, PhD</creatorcontrib><creatorcontrib>Bron, Anthony J., FRCOphth, FMedSci</creatorcontrib><creatorcontrib>Holland, Edward J., MD</creatorcontrib><creatorcontrib>McDonald, Marguerite B., MD, FACS</creatorcontrib><creatorcontrib>Nelson, J. Daniel, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmology (Rochester, Minn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Foulks, Gary N., MD, FACS</au><au>Nichols, Kelly K., OD, PhD</au><au>Bron, Anthony J., FRCOphth, FMedSci</au><au>Holland, Edward J., MD</au><au>McDonald, Marguerite B., MD, FACS</au><au>Nelson, J. Daniel, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction</atitle><jtitle>Ophthalmology (Rochester, Minn.)</jtitle><addtitle>Ophthalmology</addtitle><date>2012-10-01</date><risdate>2012</risdate><volume>119</volume><issue>10</issue><spage>S1</spage><epage>S12</epage><pages>S1-S12</pages><issn>0161-6420</issn><eissn>1549-4713</eissn><abstract>Ocular surface disorders—and dry eye, in particular—is a leading reason for visits to eye care professionals. It has been generally accepted that meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, as well as being associated with aqueous-deficient dry eye. Yet, researchers and clinicians have lacked a global consensus on the definition of MGD, its epidemiology, pathophysiology, and management. Various systemic diseases and medications have been associated with the progression of both dry eye and MGD, as have several ocular disorders beyond those directly affecting the surface. It is in the best interest of patients for clinicians to be able to better identify and diagnose MGD, differentiating it from other ocular surface disorders, and to recognize the effects of MGD on the ocular surface, and thus initiate appropriate therapy. This CME activity provides expert insight into the Tear Film and Ocular Surface Society's International Workshop on MGD consensus report, offering practical application of its findings to better manage MGD patient care, particularly for those patients facing or undergoing ocular surgery.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23034341</pmid><doi>10.1016/j.ophtha.2012.06.064</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0161-6420 |
ispartof | Ophthalmology (Rochester, Minn.), 2012-10, Vol.119 (10), p.S1-S12 |
issn | 0161-6420 1549-4713 |
language | eng |
recordid | cdi_proquest_miscellaneous_1112679347 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Adult Cyclosporine - administration & dosage Dry Eye Syndromes - diagnosis Dry Eye Syndromes - metabolism Eyelid Diseases - classification Eyelid Diseases - diagnosis Eyelid Diseases - metabolism Female Humans Keratomileusis, Laser In Situ Lacrimal Apparatus Diseases - diagnosis Lacrimal Apparatus Diseases - metabolism Male Meibomian Glands - pathology Middle Aged Ophthalmic Solutions - administration & dosage Ophthalmology Tears - metabolism Visual Acuity |
title | Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T21%3A43%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improving%20Awareness,%20Identification,%20and%20Management%20of%20Meibomian%20Gland%20Dysfunction&rft.jtitle=Ophthalmology%20(Rochester,%20Minn.)&rft.au=Foulks,%20Gary%20N.,%20MD,%20FACS&rft.date=2012-10-01&rft.volume=119&rft.issue=10&rft.spage=S1&rft.epage=S12&rft.pages=S1-S12&rft.issn=0161-6420&rft.eissn=1549-4713&rft_id=info:doi/10.1016/j.ophtha.2012.06.064&rft_dat=%3Cproquest_cross%3E1112679347%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1112679347&rft_id=info:pmid/23034341&rft_els_id=1_s2_0_S0161642012006240&rfr_iscdi=true |